DK2558068T3 - Anti-misbrug geleret farmaceutisk sammensætning - Google Patents

Anti-misbrug geleret farmaceutisk sammensætning Download PDF

Info

Publication number
DK2558068T3
DK2558068T3 DK11715601.8T DK11715601T DK2558068T3 DK 2558068 T3 DK2558068 T3 DK 2558068T3 DK 11715601 T DK11715601 T DK 11715601T DK 2558068 T3 DK2558068 T3 DK 2558068T3
Authority
DK
Denmark
Prior art keywords
abuse
pharmaceutical composition
composition
dosage unit
oil
Prior art date
Application number
DK11715601.8T
Other languages
English (en)
Inventor
Kurt Ingar Draget
Ingvild Johanne Haug
Steinar Johan Engelsen
Tore Seternes
Magnus N Hattrem
Original Assignee
Ayanda Group As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayanda Group As filed Critical Ayanda Group As
Application granted granted Critical
Publication of DK2558068T3 publication Critical patent/DK2558068T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Claims (9)

  1. ΑΝΤΙ-MISBRUG GELERET FARMACEUTISK SAMMENSÆTNING Patentkrav
    1. Oral farmaceutisk sammensætning i uovertrukket doseringsenhedsform der omfatter en fysiologisk tålelig, fleksibel, geleret bifasisk oile-i-vand emulsion indeholdende et misbrugsstof som er valgt fra gruppen bestående af kodein, morfin, hydrokodon, oxykodon, diamorfin, petidin, tramadol, buprenorfin, propoxyfen, dextropropoxyfen, hydromorfon, oxymorfon, pentazocin, levorfanol, butorfanol, ketobemidon, fentanyl, meperidin, difenoxylat, venlafaxin, nefopam, carbamazepin, gabapentin, pregabalin, tricycliske antidepressiva inkluderende amitriptylin, pentobarbitalnatrium, diazepam, alprazolam, flunitrazepam, amfetamin, I-lysin-d-amfetamin, methyl phenidat, metadon, mefedron, tetrahydrocannabinol, ketamin, clonidin, mexiletin, og tapentadol, hvor dosisenheden har en vægt på 50 til 3000 mg.
  2. 2. Sammensætningen ifølge krav 1 hvor misbrugsstoffet er i opløst eller dispergeret tilstand.
  3. 3. Sammensætningen ifølge krav 1 eller krav 2, yderligere omfattende en umættet fedtsyre.
  4. 4. Sammensætningen ifølge et hvilket som helst af de foregående krav, yderligere omfattende en ekstra komponent valgt fra lipider, vitaminer, mineraler, folsyre, pH modifikatorer, viskositet modifikatorer, smagsstoffer, aromaer, sødemidler, farvestoffer og antioxidanter.
  5. 5. Sammensætningen ifølge et hvilket som helst af de foregående krav, yderligere omfattende en citrussmag.
  6. 6. Sammensætningen ifølge et hvilket som helst af de foregående krav, yderligere omfattende xylitol.
  7. 7. Oral farmaceutisk sammensætning i uovertrukket doseringsenhedsform ifølge et hvilket som helst af kravene 1 til 6 til anvendelse i medicin.
  8. 8. Oral farmaceutisk sammensætning i uovertrukket doseringsenhedsform ifølge et hvilket som helst af kravene 1 til 6 til anvendelse i behandlingen af en tilstand der reagerer på misbrugsstoffet ved oral administration.
  9. 9. Anvendelse af et misbrugsstof til fremstillingen afen oral farmaceutisk sammensætning i uovertrukket doseringsenhedsform ifølge et hvilket som helst af kravene 1 til 6 til anvendelse ved oral administration i behandlingen afen tilstand der reagerer på misbrugsstoffet.
DK11715601.8T 2010-04-14 2011-04-11 Anti-misbrug geleret farmaceutisk sammensætning DK2558068T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1006200.8A GB201006200D0 (en) 2010-04-14 2010-04-14 Composition
PCT/GB2011/000560 WO2011128630A2 (en) 2010-04-14 2011-04-11 Anti-abuse gelled pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK2558068T3 true DK2558068T3 (da) 2017-01-23

Family

ID=42245180

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11715601.8T DK2558068T3 (da) 2010-04-14 2011-04-11 Anti-misbrug geleret farmaceutisk sammensætning

Country Status (9)

Country Link
US (2) US20130273152A1 (da)
EP (2) EP2558068B1 (da)
JP (2) JP2013523873A (da)
DK (1) DK2558068T3 (da)
EA (2) EA027150B1 (da)
ES (1) ES2613271T3 (da)
GB (2) GB201006200D0 (da)
PL (1) PL2558068T3 (da)
WO (2) WO2011128630A2 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
LT2273983T (lt) 2008-05-09 2016-10-25 Grünenthal GmbH Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
AU2010275754B2 (en) 2009-07-22 2014-05-15 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
SI2680832T1 (sl) 2011-03-04 2019-11-29 Gruenenthal Gmbh Vodna farmacevtska formulacija tapentadola za peroralno dovajanje
EA033171B1 (ru) * 2011-03-04 2019-09-30 Грюненталь Гмбх Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
LT2736497T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
AR091349A1 (es) * 2012-04-30 2015-01-28 Otsuka Pharma Co Ltd Formulacion oral
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US20150359773A1 (en) * 2012-09-26 2015-12-17 Seth D. Feuerstein Combination methods and compositions including sleep therapeutics for treating mood
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN106572980A (zh) * 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20160279078A1 (en) 2015-03-27 2016-09-29 Gruenenthal Gmbh Stable Formulation for Parenteral Administration of Tapentadol
AU2016251854A1 (en) 2015-04-24 2017-10-19 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
KR20190057349A (ko) 2016-09-23 2019-05-28 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여용 안정한 제제
EP3532068A4 (en) * 2016-10-31 2020-04-29 Suda Ltd ADMINISTRATION OF ACTIVE INGREDIENTS BY MUCOSA
CA3076963C (en) * 2017-11-30 2022-03-29 Canopy Growth Corporation Liquid dosage forms comprising cannabis, methods of making and use
CA3220214A1 (en) * 2021-05-26 2022-12-01 Abdelmalik Slassi Hallucinogen-fatty acid combination

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428927A (en) * 1981-05-11 1984-01-31 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
GB9721746D0 (en) * 1997-10-15 1997-12-10 Panos Therapeutics Limited Compositions
EP1189620B1 (en) * 1999-04-01 2004-06-23 Akzo Nobel N.V. Formulation comprising testosteron undecanoate and castor oil
WO2002024165A2 (en) * 2000-09-20 2002-03-28 Nycomed Pharma As Preparation of vitamin emulsions and concentrates thereof
AU2003217436A1 (en) * 2002-02-15 2003-09-09 Howard Brooks-Korn Use of opioid compound to treat a neurologic or neurogenic disorder
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
EP2959893A1 (en) * 2002-12-13 2015-12-30 DURECT Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
LT1765292T (lt) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Nuo piktnaudžiavimo apsaugotos vaistų formos
GB0506982D0 (en) * 2005-04-06 2005-05-11 Mw Encap Ltd Abuse resistant capsules
WO2006133733A1 (en) * 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
EP1904845A4 (en) 2005-07-07 2009-11-25 David E Kohne IMPROVED RESULTS AND APPLICATION OF COMPARISON EXAMPLES OF PROTEIN EXPRESSIONS
US9125833B2 (en) * 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
DK1903866T3 (da) * 2005-11-07 2016-07-25 Murty Pharmaceuticals Inc Forbedret afgivelse af tetrahydrocannabinol
EP1968567B1 (en) * 2005-12-20 2014-06-18 Cenestra, Llc Omega 3 fatty acid formulations
GB0601498D0 (en) 2006-01-25 2006-03-08 Probio Nutraceuticals As Product
ITMI20072051A1 (it) * 2007-10-23 2009-04-24 Chimico Internaz S P A In Brev Composizione a base di pellet di acido lipoico
GB0801643D0 (en) 2008-01-29 2008-03-05 Probio Nutraceuticals As Product
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB0818472D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB201006214D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition

Also Published As

Publication number Publication date
EA201290984A1 (ru) 2013-05-30
WO2011128630A2 (en) 2011-10-20
JP2013523873A (ja) 2013-06-17
EP2558078A2 (en) 2013-02-20
EA201290982A1 (ru) 2013-09-30
US20130274280A1 (en) 2013-10-17
EP2558068A2 (en) 2013-02-20
WO2011128630A3 (en) 2012-06-28
GB201006699D0 (en) 2010-06-09
US20130273152A1 (en) 2013-10-17
JP2013527152A (ja) 2013-06-27
GB201006200D0 (en) 2010-06-02
JP5903092B2 (ja) 2016-04-13
PL2558068T3 (pl) 2017-04-28
EA027150B1 (ru) 2017-06-30
EP2558068B1 (en) 2016-11-30
ES2613271T3 (es) 2017-05-23
WO2011128635A2 (en) 2011-10-20
WO2011128635A3 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
DK2558068T3 (da) Anti-misbrug geleret farmaceutisk sammensætning
JP5978276B2 (ja) 乱用可能性が低減された医薬組成物
EP1868585B1 (en) Abuse resistant capsules
ES2592504T3 (es) Preparaciones de liberación controlada
US20170296467A1 (en) Chewable gelled emulsions
JP6067676B2 (ja) 経口医薬分散組成物
WO2011128634A2 (en) Over the counter pharmaceutical compositions
JP2014012685A (ja) 全身性医薬品の経口媒体
US20130280317A1 (en) Coated nutraceutical and pharmaceutical compositions
WO2011128626A1 (en) Essential fatty acid gelled composition
Hedaya et al. The Need for Tamper-Resistant and Abuse-Deterrent Formulations
JP2017019847A (ja) 経口医薬分散組成物
WO2011128631A2 (en) Vegetarian oral pharmaceutical and nutraceutical compositions
MX2008003374A (es) Vehiculo oral para productos farmaceuticos sistemicos